Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolerability of SC IgG with Varying Injection Conditions in Healthy Participants
NCT07025577Phase 1Completed
- Sponsor
- Genentech
- Start
- Jun 2025
- Primary completion
- Aug 2025
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of IgPro10 in primary immunodeficiency (PI) (4 arms), sponsored by Genentech. Primary endpoints: Mean Injection Site Tolerability Score on a Visual Analogue Scale (VAS), Mean Change From Baseline in Injection Site Tolerability Score on VAS and 5 more. Started Jun 2025; status: completed.
02
Drugs
IgPro10
03
Conditions
primary immunodeficiency (PI)
Beyond the preview
Go deeper on NCT07025577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07025577.